Ustekinumab, which targets the shared p40 subunit of IL-12 and IL-23, is already approved for Crohn’s disease and psoriasis, and, in the context of SAPHO-IBD overlap, has demonstrated benefit across gastrointestinal, cutaneous, and osteoarticular domains [65-67]. This evidence concerns the gene IL37 and inflammatory bowel disease.